ATE473739T1 - Verwendung eines benzoyl-derivats von 3- aminocarbazol zur behandlung einer erkrankung im zusammenhang mit der erzeugung von prostaglandin e2 (pge2) - Google Patents
Verwendung eines benzoyl-derivats von 3- aminocarbazol zur behandlung einer erkrankung im zusammenhang mit der erzeugung von prostaglandin e2 (pge2)Info
- Publication number
- ATE473739T1 ATE473739T1 AT06753538T AT06753538T ATE473739T1 AT E473739 T1 ATE473739 T1 AT E473739T1 AT 06753538 T AT06753538 T AT 06753538T AT 06753538 T AT06753538 T AT 06753538T AT E473739 T1 ATE473739 T1 AT E473739T1
- Authority
- AT
- Austria
- Prior art keywords
- aminocarbazole
- pge2
- prostaglandin
- generation
- treatment
- Prior art date
Links
- -1 BENZOYL DERIVATIVE OF 3-AMINOCARBAZOLE Chemical class 0.000 title 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000909A ITMI20050909A1 (it) | 2005-05-19 | 2005-05-19 | Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2- |
| PCT/EP2006/004348 WO2006122680A1 (en) | 2005-05-19 | 2006-05-03 | Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE473739T1 true ATE473739T1 (de) | 2010-07-15 |
Family
ID=35219704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06753538T ATE473739T1 (de) | 2005-05-19 | 2006-05-03 | Verwendung eines benzoyl-derivats von 3- aminocarbazol zur behandlung einer erkrankung im zusammenhang mit der erzeugung von prostaglandin e2 (pge2) |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8686021B2 (enExample) |
| EP (1) | EP1881826B1 (enExample) |
| JP (1) | JP5086991B2 (enExample) |
| KR (1) | KR101312579B1 (enExample) |
| CN (1) | CN101166528B (enExample) |
| AR (1) | AR054126A1 (enExample) |
| AT (1) | ATE473739T1 (enExample) |
| AU (1) | AU2006246688B2 (enExample) |
| BR (1) | BRPI0609718A2 (enExample) |
| CA (1) | CA2604562C (enExample) |
| DE (1) | DE602006015457D1 (enExample) |
| DK (1) | DK1881826T3 (enExample) |
| EA (1) | EA012724B1 (enExample) |
| ES (1) | ES2347174T3 (enExample) |
| GE (1) | GEP20094738B (enExample) |
| IL (1) | IL186072A (enExample) |
| IT (1) | ITMI20050909A1 (enExample) |
| MX (1) | MX2007013491A (enExample) |
| PL (1) | PL1881826T3 (enExample) |
| PT (1) | PT1881826E (enExample) |
| SI (1) | SI1881826T1 (enExample) |
| UA (1) | UA94044C2 (enExample) |
| WO (1) | WO2006122680A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20051523A1 (it) | 2005-08-03 | 2007-02-04 | Acraf | Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo |
| EP2119705A1 (en) | 2008-05-14 | 2009-11-18 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor |
| US8880004B2 (en) | 2009-05-14 | 2014-11-04 | Qualcomm Incorporated | System and method for resolving conflicts between air interfaces in a wireless communication system |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241368A (ja) * | 1997-02-18 | 2002-08-28 | Shionogi & Co Ltd | 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物 |
| US6399631B1 (en) | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
| AU6000900A (en) | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| JP2003507424A (ja) * | 1999-08-26 | 2003-02-25 | ブリストル−マイヤーズ スクイブ カンパニー | Ｎｐｙアンタゴニスト：スピロイソキノリノン誘導体 |
| DE10125961A1 (de) | 2001-05-29 | 2002-12-12 | Boehringer Ingelheim Int | Carbazolderivate und deren Verwendung zur Herstellung einer Arzneimittelzusammensetzung zur Behandlung von im Zusammenhang mit NPY stehenden Leiden |
| CA2403307A1 (en) * | 2001-10-23 | 2003-04-23 | Neurogen Corporation | Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives |
| KR20030042344A (ko) * | 2001-11-22 | 2003-05-28 | 한국생명공학연구원 | 에레모필란계 화합물 또는 곰취추출물을 유효성분으로함유하는 염증질환 치료제, 면역질환 치료제, 및 암 치료제 |
| ES2193875B2 (es) * | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
| KR100402714B1 (ko) * | 2002-12-23 | 2003-11-13 | 한국생명공학연구원 | 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도 |
-
2005
- 2005-05-19 IT IT000909A patent/ITMI20050909A1/it unknown
-
2006
- 2006-05-03 CN CN2006800144162A patent/CN101166528B/zh not_active Expired - Fee Related
- 2006-05-03 PL PL06753538T patent/PL1881826T3/pl unknown
- 2006-05-03 EP EP06753538A patent/EP1881826B1/en not_active Not-in-force
- 2006-05-03 PT PT06753538T patent/PT1881826E/pt unknown
- 2006-05-03 MX MX2007013491A patent/MX2007013491A/es active IP Right Grant
- 2006-05-03 DK DK06753538.5T patent/DK1881826T3/da active
- 2006-05-03 KR KR1020077029661A patent/KR101312579B1/ko not_active Expired - Fee Related
- 2006-05-03 WO PCT/EP2006/004348 patent/WO2006122680A1/en not_active Ceased
- 2006-05-03 JP JP2008511591A patent/JP5086991B2/ja not_active Expired - Fee Related
- 2006-05-03 GE GEAP200610441A patent/GEP20094738B/en unknown
- 2006-05-03 DE DE602006015457T patent/DE602006015457D1/de active Active
- 2006-05-03 BR BRPI0609718-9A patent/BRPI0609718A2/pt not_active IP Right Cessation
- 2006-05-03 AT AT06753538T patent/ATE473739T1/de active
- 2006-05-03 SI SI200630781T patent/SI1881826T1/sl unknown
- 2006-05-03 UA UAA200713598A patent/UA94044C2/ru unknown
- 2006-05-03 AU AU2006246688A patent/AU2006246688B2/en not_active Ceased
- 2006-05-03 EA EA200702534A patent/EA012724B1/ru not_active IP Right Cessation
- 2006-05-03 CA CA2604562A patent/CA2604562C/en not_active Expired - Fee Related
- 2006-05-03 US US11/909,393 patent/US8686021B2/en not_active Expired - Fee Related
- 2006-05-03 ES ES06753538T patent/ES2347174T3/es active Active
- 2006-05-17 AR ARP060101981A patent/AR054126A1/es not_active Application Discontinuation
-
2007
- 2007-09-19 IL IL186072A patent/IL186072A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101166528A (zh) | 2008-04-23 |
| EP1881826A1 (en) | 2008-01-30 |
| IL186072A0 (en) | 2008-08-07 |
| CA2604562C (en) | 2013-09-17 |
| ITMI20050909A1 (it) | 2006-11-20 |
| IL186072A (en) | 2012-05-31 |
| ES2347174T3 (es) | 2010-10-26 |
| PT1881826E (pt) | 2010-08-05 |
| CN101166528B (zh) | 2011-06-15 |
| AU2006246688A1 (en) | 2006-11-23 |
| UA94044C2 (ru) | 2011-04-11 |
| JP2008540591A (ja) | 2008-11-20 |
| JP5086991B2 (ja) | 2012-11-28 |
| KR101312579B1 (ko) | 2013-09-30 |
| KR20080018898A (ko) | 2008-02-28 |
| SI1881826T1 (sl) | 2010-10-29 |
| WO2006122680A1 (en) | 2006-11-23 |
| GEP20094738B (en) | 2009-07-27 |
| MX2007013491A (es) | 2008-01-24 |
| PL1881826T3 (pl) | 2010-12-31 |
| CA2604562A1 (en) | 2006-11-23 |
| AR054126A1 (es) | 2007-06-06 |
| US20080287518A1 (en) | 2008-11-20 |
| BRPI0609718A2 (pt) | 2011-10-18 |
| EP1881826B1 (en) | 2010-07-14 |
| EA012724B1 (ru) | 2009-12-30 |
| DE602006015457D1 (de) | 2010-08-26 |
| HK1119571A1 (en) | 2009-03-13 |
| EA200702534A1 (ru) | 2008-04-28 |
| AU2006246688B2 (en) | 2011-09-22 |
| US8686021B2 (en) | 2014-04-01 |
| DK1881826T3 (da) | 2010-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3133070T (lt) | Eligliustatas (genz 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti fabri arba gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento p-450 metabolizmui | |
| EA200801013A1 (ru) | Производные замещённых соединений, содержащих конденсированные бензольные кольца, и их применение в качестве лигандов ванилоидных рецепторов | |
| DE602007008126D1 (de) | Verfahren zur herstellung von (s)-4-fluormethyldihydrofuran-2-on | |
| EA201100969A1 (ru) | Солевые формы органического соединения | |
| CY1115180T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
| EA200970402A1 (ru) | Триазолопиридазиновые модуляторы протеинкиназ | |
| ATE534633T1 (de) | Indazolderivate zur behandlung von hsp90- induzierten krankheiten | |
| EA201100517A1 (ru) | Способ получения дабигатрана и его промежуточные соединения | |
| ATE539054T1 (de) | Verfahren zur herstellung von dihydropyrrolderivaten als zwischenprodukte | |
| ATE510536T1 (de) | Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
| ATE438623T1 (de) | Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes | |
| EA201071120A1 (ru) | Способ получения гетероарилбензопроизводных сульфаматов и кристаллической формы n-((2s)-6-хлор-2,3-дигидро-l,4-бензодиоксин-2-ил)метилсульфамида | |
| ATE473735T1 (de) | Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut | |
| ATE464895T1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen | |
| ATE539743T1 (de) | Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan | |
| EA201170114A1 (ru) | Способ получения бензоимидазол-2-илпиримидиновых производных | |
| ATE492534T1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| ATE473739T1 (de) | Verwendung eines benzoyl-derivats von 3- aminocarbazol zur behandlung einer erkrankung im zusammenhang mit der erzeugung von prostaglandin e2 (pge2) | |
| DE102006060366B8 (de) | Verfahren zur Herstellung von von einer Matrix abgedeckten Quantenpunkten | |
| ATE522210T1 (de) | Zusammensetzungen umfassend alpha-ketoglutarat und ihre verwendung zur modulierung der muskelleistung | |
| MX2011002309A (es) | Anticuerpos de aves especificos para virus de influenza y metodos tecnologicamente sencillos de su fabricacion y uso. | |
| GT200900037A (es) | Compuestos organicos | |
| ATE520393T1 (de) | Verwendung von cb1-rezeptor-antagonisten zur herstellung eines arzneimittels zur behandlung von lebererkrankungen | |
| EA200901171A1 (ru) | Кристаллические формы 2-[2-хлор-4-метилсульфонил-3-(2,2,2-трифторэтоксиметил)бензоил]циклогексан-1,3-диона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1881826 Country of ref document: EP |